These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26850319)

  • 1. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts.
    Fink KD; Deng P; Gutierrez J; Anderson JS; Torrest A; Komarla A; Kalomoiris S; Cary W; Anderson JD; Gruenloh W; Duffy A; Tempkin T; Annett G; Wheelock V; Segal DJ; Nolta JA
    Cell Transplant; 2016; 25(4):677-86. PubMed ID: 26850319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.
    Shin JW; Kim KH; Chao MJ; Atwal RS; Gillis T; MacDonald ME; Gusella JF; Lee JM
    Hum Mol Genet; 2016 Oct; 25(20):4566-4576. PubMed ID: 28172889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
    van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
    Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
    Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
    Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities.
    Oikemus SR; Pfister EL; Sapp E; Chase KO; Kennington LA; Hudgens E; Miller R; Zhu LJ; Chaudhary A; Mick EO; Sena-Esteves M; Wolfe SA; DiFiglia M; Aronin N; Brodsky MH
    Hum Gene Ther; 2022 Jan; 33(1-2):25-36. PubMed ID: 34376056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
    Monteys AM; Ebanks SA; Keiser MS; Davidson BL
    Mol Ther; 2017 Jan; 25(1):12-23. PubMed ID: 28129107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.
    Miller JRC; Pfister EL; Liu W; Andre R; Träger U; Kennington LA; Lo K; Dijkstra S; Macdonald D; Ostroff G; Aronin N; Tabrizi SJ
    Sci Rep; 2017 Apr; 7():46740. PubMed ID: 28436437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene targeting techniques for Huntington's disease.
    Fields E; Vaughan E; Tripu D; Lim I; Shrout K; Conway J; Salib N; Lee Y; Dhamsania A; Jacobsen M; Woo A; Xue H; Cao K
    Ageing Res Rev; 2021 Sep; 70():101385. PubMed ID: 34098113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Making (anti-) sense out of huntingtin levels in Huntington disease.
    Evers MM; Schut MH; Pepers BA; Atalar M; van Belzen MJ; Faull RL; Roos RA; van Roon-Mom WM
    Mol Neurodegener; 2015 Apr; 10():21. PubMed ID: 25928884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.
    Østergaard ME; Southwell AL; Kordasiewicz H; Watt AT; Skotte NH; Doty CN; Vaid K; Villanueva EB; Swayze EE; Bennett CF; Hayden MR; Seth PP
    Nucleic Acids Res; 2013 Nov; 41(21):9634-50. PubMed ID: 23963702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease.
    Klempíř J; Zidovská J; Stochl J; Ing VK; Uhrová T; Roth J
    Mov Disord; 2011 Jan; 26(1):125-9. PubMed ID: 21322024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VCP cooperates with UBXD1 to degrade mitochondrial outer membrane protein MCL1 in model of Huntington's disease.
    Guo X; Qi X
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):552-559. PubMed ID: 27913212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haplotype-based stratification of Huntington's disease.
    Chao MJ; Gillis T; Atwal RS; Mysore JS; Arjomand J; Harold D; Holmans P; Jones L; Orth M; Myers RH; Kwak S; Wheeler VC; MacDonald ME; Gusella JF; Lee JM
    Eur J Hum Genet; 2017 Nov; 25(11):1202-1209. PubMed ID: 28832564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin.
    Connolly C; Magnusson-Lind A; Lu G; Wagner PK; Southwell AL; Hayden MR; Björkqvist M; Leavitt BR
    Neuroscience; 2016 Jun; 325():74-88. PubMed ID: 27033979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of normal and mutant Huntington's disease gene alleles.
    Persichetti F; Carlee L; Faber PW; McNeil SM; Ambrose CM; Srinidhi J; Anderson M; Barnes GT; Gusella JF; MacDonald ME
    Neurobiol Dis; 1996; 3(3):183-90. PubMed ID: 8980018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.
    Conroy F; Miller R; Alterman JF; Hassler MR; Echeverria D; Godinho BMDC; Knox EG; Sapp E; Sousa J; Yamada K; Mahmood F; Boudi A; Kegel-Gleason K; DiFiglia M; Aronin N; Khvorova A; Pfister EL
    Nat Commun; 2022 Oct; 13(1):5802. PubMed ID: 36192390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.